Related Experiment Video
Updated: Feb 13, 2026

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
[18F] AV-1451 uptake in corticobasal syndrome: the influence of beta-amyloid and clinical presentation
F Ali1, J L Whitwell2, P R Martin3
1Department of Neurology, Mayo Clinic, 200 1st St SW, Rochester, MN, 55905, USA. ali.farwa@mayo.edu.
Molecular neuroimaging with [18F] AV-1451 PET in corticobasal syndrome (CBS) shows variable tau uptake patterns. Uptake depends on beta-amyloid status and clinical presentation, such as apraxia of speech (AOS).
Area of Science:
- Neuroimaging
- Neuropathology
- Nuclear Medicine
Background:
- Corticobasal syndrome (CBS) presents with diverse underlying pathologies, making accurate diagnosis challenging.
- Predicting the specific pathology in CBS is often unreliable.
- Molecular neuroimaging offers a potential tool for improved pathological assessment in CBS.
Purpose of the Study:
- To investigate regional [18F] AV-1451 positron emission tomography (PET) uptake patterns in patients with CBS.
- To determine if [18F] AV-1451 uptake patterns differ based on beta-amyloid (Aβ) deposition status.
- To explore variations in [18F] AV-1451 uptake related to distinct clinical presentations, specifically comparing typical CBS with apraxia of speech (AOS).
Main Methods:
- Fourteen patients meeting CBS criteria underwent both Pittsburgh Compound B (PiB) PET and [18F] AV-1451 PET scans.
- Patients were categorized as PiB-positive (PiB+) or PiB-negative (PiB-) based on global PiB uptake.
- Standardized uptake value ratios (SUVRs) for [18F] AV-1451 were calculated in 14 regions of interest and compared to a control group.
Main Results:
- 43% of CBS patients were PiB+; three showed widespread cortical [18F] AV-1451 uptake.
- In PiB-negative CBS patients, elevated [18F] AV-1451 uptake in specific motor regions was observed only in those with a history of AOS.
- PiB-negative CBS patients without AOS did not exhibit elevated [18F] AV-1451 uptake in any region compared to controls.
Conclusions:
- Regional [18F] AV-1451 uptake in CBS is variable and influenced by both beta-amyloid presence and clinical phenotype, including AOS.
- PiB-positive CBS does not definitively confirm Alzheimer's disease but warrants monitoring for potential evolution.
- Molecular imaging patterns can provide insights into the heterogeneity of CBS pathologies.
More Related Videos
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid Fibrils
Self-Presentation
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Self-Presentation: Self-Monitoring and Self-Handicapping
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:

